Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has been approved based on the clinical benefit in non-small cell lung cancer (NSCLC) patients over the past decade. Unfortunately, cancer cells become resistant to this agent via various mechanisms, and this limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Caifeng, Jin, Jiangbo, Bao, Xujie, Zhan, Wei-Hua, Han, Tian-Yu, Gan, Mingxi, Zhang, Chengfu, Wang, Jianbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808021/
https://www.ncbi.nlm.nih.gov/pubmed/26575584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808021/
https://www.ncbi.nlm.nih.gov/pubmed/26575584

Ejemplares similares